Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 117
A Review of the Department of Defense's Program for Breast Cancer Research APPENDIX C ''Dear Colleague" Letter INSTITUTE OF MEDICINE NATIONAL ACADEMY OF SCIENCES 2101 CONSTITUTION AVENUE, N.W. WASHINGTON, D.C. 20418 COMMITTEE ON BREAST CANCER RESEARCH PHONE (202) 334-1917 FAX (202) 334-2316 October 18, 1996 Dear Colleague, As you know, Congress has allocated well over $400 million to the Department of Defense (DOD) since 1993 and designated the U.S. Army Medical Research and Materiel Command to oversee the Breast Cancer Research Program. This program is currently being reviewed and evaluated by an independent scientific committee appointed by the Institute of Medicine (IOM). An important part of this process is gathering information about scientists' experiences as grant applicants and, subsequently, as grantees. We are inviting you to comment on the DOD's implementation of this grant program. Please feel free to comment on: (1) specific aspects of the program (e.g., procedures for proposal submission, peer review, budgetary review and tracking, protection of study participants, and project oversight), and (2) the program overall. Please submit your comments anonymously. For your convenience, we have provided a return label.
OCR for page 118
A Review of the Department of Defense's Program for Breast Cancer Research The grantees' perspective will play an important part in the committee's deliberations. Please limit your comments to two pages. Because of the short time frame for this study, we need to receive your responses no later than November 1, 1996. We encourage you to fax your response to 202-334-2316. We appreciate you cooperation. Sincerely, Mary Poos Study Director Committee on Breast Cancer Research Sincerely, George Davatelis Program Officer Committee on Breast Cancer Research
Representative terms from entire chapter: